Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Concerns about potential pharma tariffs began before Trump took office after he repeatedly threatened a 25% tariff.

The best value stocks have an attractive fundamental valuation, a healthy balance sheet, a stable or growing market share in ...

Merck (MRK) announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of ...

The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Merck & Co. is flexing its dividend muscles with 14 years of consecutive growth and a yield that's juicier than a ripe ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.